8
ALL8
Ginkgo BioworksYear
8
ALL1
20251
20243
20231
20221
20211
2020DEALS // DEV.
8
ALL8
DealsCountry
8
ALL8
U.S.A8
ALL1
Bill & Melinda Gates Foundation1
Biogen1
Boehringer Ingelheim GmbH1
Moderna Therapeutics2
Novo Nordisk1
Pfizer Inc1
Universal CellsTherapeutic Area
8
ALL2
Endocrinology2
Infections and Infectious Diseases1
Neurology1
Oncology2
TechnologyStudy Phase
8
ALL1
Phase I1
Discovery Platform5
Discovery1
UndisclosedDeal Type
8
ALL5
Collaboration1
Expanded Collaboration1
Funding1
PartnershipProduct Type
8
ALL1
Cell and Gene therapy6
Undisclosed1
VaccineDosage Form
8
ALL1
Implant1
Intramuscular Injection3
Oral3
UndisclosedLead Product
8
ALL1
TAK-9197
UndisclosedTarget
8
ALL1
SARS-CoV-2-viral spike protein7
UndisclosedLead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Universal Cells
Deal Size : Undisclosed
Deal Type : Collaboration
Ginkgo Bioworks Partners with Universal Cells to Advance iPSC-Derived Therapies
Details : This collaboration underscores Ginkgo's capacity to deploy high-throughput biological approaches to tackle the complex challenge set associated with development of therapies targeting solid tumors.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 13, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Universal Cells
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain
Details : The partnership aims to enhance the manufacturing of Novo's medicines for serious chronic diseases, including diabetes and obesity, leveraging Ginkgo's synthetic biology platform for new methods.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Details : The financing will be used to develop a novel live cell therapeutic that can produce antibodies to fight human immunodeficiency virus (HIV) and/or malaria directly in the body.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 13, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Pfizer Inc
Deal Size : $331.0 million
Deal Type : Collaboration
Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer
Details : Under the collaboration, Pfizer will leverage Ginkgo's proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 27, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Pfizer Inc
Deal Size : $331.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $406.0 million
Deal Type : Partnership
Details : The companies will leverage Ginkgo's natural product discovery capabilities to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $406.0 million
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Collaboration
Ginkgo Bioworks and Novo Nordisk to Collaborate on Expression Systems for Pharmaceutical Products
Details : Using synthetic biology, Ginkgo and Novo Nordisk will collaborate to unlock the potential of expression systems, which may accelerate and enhance the discovery and development of Novo Nordisk's biological medicines.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 06, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Biogen
Deal Size : $120.0 million
Deal Type : Collaboration
Details : Biogen will receive access to Ginkgo’s proprietary cell programming platform and capabilities. Ginkgo will utilize its bioengineering facilities and resources with the aim of enhancing the AAV production titers of Biogen’s gene therapy manufacturing ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $5.0 million
May 21, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Biogen
Deal Size : $120.0 million
Deal Type : Collaboration
Lead Product(s) : TAK-919
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Ginkgo Bioworks Provides Support on Process Optimization to Moderna for COVID-19 Response
Details : The deal is focused on exploring potential optimizations to Moderna's processes for generating some of the key raw materials used in the manufacturing of its mRNA vaccines, including for mRNA-1273.
Product Name : mRNA-1273
Product Type : Vaccine
Upfront Cash : Undisclosed
April 15, 2020
Lead Product(s) : TAK-919
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration